Ameriprise Financial Inc Satsuma Pharmaceuticals, Inc. Transaction History

Ameriprise Financial Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.19 - $7.95 $165,002 - $313,071	39,380 Added 5.2%	796,865 $4.78 Million
Q2 2022 Aug 15, 2022	BUY	$2.59 - $4.3 $13,229 - $21,964	5,108 Added 0.68%	757,485 $3.14 Million
Q1 2022 May 16, 2022	BUY	$3.78 - $5.32 $190,031 - $267,452	50,273 Added 7.16%	752,377 $2.86 Million
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $283,818 - $426,753	-68,390 Reduced 8.88%	702,104 $3.16 Million
Q3 2021 Nov 15, 2021	BUY	$4.54 - $7.17 $564,340 - $891,259	124,304 Added 19.24%	770,494 $3.59 Million
Q2 2021 Aug 16, 2021	BUY	$4.8 - $7.25 $3.1 Million - $4.68 Million	646,190 New	646,190 $4.56 Million

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.